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Serotonin re-uptake transporter 
gene polymorphisms are associated 
with imatinib-induced diarrhoea in 
chronic myeloid leukaemia patients
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tyrosine kinase inhibitors (tKis), the treatment of choice for chronic myeloid leukaemia (cML), can 
cause lower gastrointestinal (Gi) toxicity which is manifested as diarrhoea. the mechanisms are 
not fully understood. The enteroendocrine signalling compound, serotonin (5-HT), is important for 
regulating peristaltic motion, fluid secretion and visceral hypersensitivity in the GI tract, and has been 
implicated in diseases such as irritable bowel syndrome. in this study, we have evaluated whether tKi-
induced diarrhoea may be related to variation in the serotonin re-uptake transporter (SeRt) gene. cML 
patients with and without diarrhoea on the SPIRIT2 trial (imatinib, n = 319; and dasatinib, n = 297) 
were genotyped for the promoter 5-HTTLPR, intron 2 VNTR and rs25531 polymorphisms by PCR-based 
methods. Diarrhoea was more prevalent in imatinib, than in dasatinib treated patients (p = 0.015), 
which when stratified by gender was seen to be driven by female patients (P = 0.036). Logistic 
regression analysis revealed that age, and the dominant HTTLPR with the rs25531 single nucleotide 
polymorphism (SNP) model, explained the occurrence of diarrhoea in ~10% of imatinib-treated female 
CML patients. These data suggest SERT polymorphisms influence imatinib-induced diarrhoea but not 
that of dasatinib.
Tyrosine kinase inhibitor drugs (TKIs) are now the mainstay of treatment for chronic myeloid leukaemia (CML). 
Several are now available, and a meta-analysis of first-line treatment options for CML showed that there was 
little difference seen across all TKIs regarding complete cytogenetic response (CCyR), progression-free survival 
(PFS) and overall survival (OS) outcomes1. The choice of therapy can be dictated by many factors including the 
occurrence of adverse events (AEs).
Diarrhoea is a common socially debilitating AE associated with TKIs. Imatinib causes diarrhoea of any grade 
in ~25% of CML patients2. Higher imatinib dose, in the phase 2 SWOG S0325 trial, increased the incidence, 
but not necessarily the grade of diarrhoea from 39% to 56%3. Dasatinib caused diarrhoea in 1 in 5 patients in 
the DASISION trial, similar to that seen with imatinib4. By contrast, the second generation TKI, bosutinib, was 
responsible for diarrhoea in up to 84% of patients in the BELA trial5 and the NCT00261846 phase1/2 study6. The 
mechanisms or predisposing factors for TKI-related diarrhoea are poorly understood.
In broad terms, diarrhoea can occur through either secretory or enteroendocrine/neuronal pathways. 
Secretory diarrhoea results from ion flux across the cell membrane that potentiates the movement of water, a 
phenomenon called ‘solvent drag’. Enteroendocrine induced diarrhoea is stimulated by neurotransmitters such as 
serotonin (5-hydroxytryptamine; 5-HT), vasoactive intestinal peptide and acetylcholine which can alter motility 
and fluid secretion of the gut7.
Serotonin (5-HT) is important for regulating peristaltic motion, fluid secretion and visceral hypersensitivity in 
the gastro-intestinal (GI) tract7. Approximately 90% of the body’s total 5-HT is located within enterochromaffin 
cells (ECs) in the GI epithelium. Release of 5-HT at neuronal synapses and into the circulation stimulates bowel 
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urgency and movement by binding to 5-HT receptors that predominate in the GI tract8. Regulation of circulatory 
levels of 5-HT is performed by the serotonin reuptake transporter (SERT). Both GI epithelial cells and platelets 
express high levels of SERT and are therefore capable of sequestering excess 5-HT which, when required, can be 
released as part of a tissue damage response7.
The SERT protein is encoded by the SLC6A4 (solute carrier family 6 member 4) gene, which has a highly pol-
ymorphic promoter region – the serotonin-transporter-linked polymorphic region (5-HTTLPR) (rs4795541)9. A 
common insertion/deletion (indel) polymorphism within the 5-HTTLPR generates two transcripts, a long allele 
(L) containing a sequence of 43 or 44 base pairs (depending on the presence of a single deletion single nucleotide 
polymorphism (SNP) rs1462091560), and a short allele (S) in which this sequence is deleted9. The short form 
is associated with 2–3-fold reduced SERT expression when compared to the long form10–12. The rs25531 SNP 
G-allele, located within the 5-HTTLPR, creates a functional AP2 transcription-factor binding site which converts 
the L-allele phenotype to that of the S-allele13. The intronic STin2 VNTR 17 bp tandem repeat (rs57098334) has 
4 known alleles consisting of 12, 10, 9 and 7 repeats. The functional influence of the 12 and 10 tandem repeats 
were tested in a transgenic embryonic mouse model which showed that the longer sequence acted as a stronger 
transcriptional inducer than the shorter sequence14.
Circulating levels of 5-HT are elevated in patients who suffer from diarrhoea-related irritable bowel syndrome 
(IBS-D) while those who experience the constipation equivalent (IBS-C) disease have low 5-HT levels15. The 
association of polymorphic variants within the 5-HTTLPR promoter region with IBS has been inconsistent16–19, 
with a recent meta-analysis of 27 IBS studies in Asian and Caucasian individuals showing that 5-HTTLPR pol-
ymorphisms did not correlate with IBS-D20. However, the SERT knock-out mouse also experiences increased 
bowel motility and diarrhoea21. Interestingly, bosutinib, which has the highest incidence of diarrhoea amongst the 
TKIs, inhibits SERT by 71% as an off-target effect22 suggesting bosutinib-induced diarrhoea may occur through 
elevated circulating 5-HT levels. We therefore hypothesised that TKI-induced diarrhoea is a result of increased 
circulating 5-HT levels with genetic polymorphisms in the SERT gene acting as predisposing factors. In order to 
investigate this, we have evaluated the commonly reported intronic STin2 VNTR, and the promoter (5-HTTLPR) 
‘long’ and ‘short’ indel variants with the rs25531 SNP, in imatinib and dasatinib treated CML patients as part of 
the SPIRIT2 randomised trial.
Results
patient characteristics. Of the patients recruited to the SPIRIT2 trial, we excluded patients from this study 
for the following reasons: 1) no consent or sample given; 2) mention of constipation; 3) co-morbidities involving 
the GI tract; 4) documented co-medications that would influence diarrhoea or serotonin levels including selective 
serotonin re-uptake inhibitors; and 5) no PCR product due to poor DNA. This left 319 imatinib and 297 dasat-
inib-treated patients who were finally included in the study (Supplementary Fig. 1). There were no significant 
differences between imatinib and dasatinib patient groups regarding age, BMI or platelet count (Table 1).
Allelic frequencies. The rs25531 SNP and 5-HTTLPR promoter indel polymorphism (rs4795541) did not 
deviate from the Hardy-Weinberg Equilibrium (HWE) within the imatinib and dasatinib-treated CML cohorts 
(Table 2). The tri-allelic STin2 VNTR polymorphism however showed significant deviation from HWE in both 
imatinib (χ2 = 24.1537; P = 0.0002) and dasatinib (χ2 = 19.0302; P = 0.0019) arms. Our observed minor allele 
frequency (MAF) for rs25531 was 7%, which is consistent with the reported Caucasian frequency of 9% on the 
HaploReg v4.1 website23. A study performed in 2622 European-American subjects, using the National Institute 
of Mental Health repository, found that the 5-HTTLPR short allele frequency was 43%24, which is identical to 
our findings. The frequencies of the STin2 VNTR 12, 10 and 9 alleles in our cohort were 62%, ~36% and ~2.5% 
respectively. Our frequency of 12 and 10 alleles are consistent with various addiction and disorder studies within 
a predominantly Caucasian background, but we have detected twice the frequency of 9 allele carriers than these 
published studies25–28. Our major deviation from the HWE was also replicated by these groups. We did not iden-
tify any carriers of the 7-repeat length STin2 VNTR in our patient cohort.
incidence of diarrhoea is more prevalent with imatinib treatment and driven by gender and 
5-HTTLPR genotype. A comparison of means test demonstrated the imatinib group had a greater incidence 
of diarrhoea compared with dasatinib (P = 0.015; 95% CI = 0.018, 0.165). When separated by gender, this signif-
icance was seen to be driven by female (P = 0.036; 95% CI = 0.009, 0.255) but not male patients (P = 0.219; 95% 
CI = −0.034, 0.146) (Table 1 & Fig. 1A).
Logistic regression analysis incorporating all patients (n = 616) showed drug (P = 0.015), gender (P = 0.002), 
age (P = 0.049), BMI (P = 0.034) and the dominant HTTLPR model (P = 0.049) were significant covariates for 
the dependent variable of diarrhoea (Table 3). After retaining these covariates in a forward conditional regression 
analysis, only gender and BMI were retained in the model explaining diarrhoea as an adverse event in 3.4% of the 
patient cohort.
On further separation of the patients by the drug received, however, none of the tested covariates were sig-
nificant for the dasatinib cohort. The significant differences were driven by the imatinib-treated patient cohort, 
and included gender (P = 0.007), 5-HTTLPR genotype (P = 0.020 and P = 0.021), especially of the dominant 
allele model (P = 0.012 and P = 0.0004), with or without the rs25531 SNP combined, respectively, and the STin2 
VNTR (P = 0.043) polymorphism. After including these covariates in a forward conditional regression analysis, 
gender enhanced the 5-HTTLPR dominant model to explain diarrhoea in 7.8% of the imatinib-treated patients. 
By further stratifying the imatinib cohort by gender, only the 5-HTTLPR dominant model explained ~6% of male 
diarrhoea cases, but age and the 5-HTTLPR plus the rs25531 dominant model explained nearly 10% of diarrhoea 
cases for females (Table 4).
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To ascertain which alleles influenced imatinib-induced diarrhoea incidence, we performed Chi-square analy-
ses. The ‘long’ allele of the 5-HTTLPR genotype alone correlated with a greater incidence of diarrhoea (P = 0.001) 
(Fig. 2A). The association was still significant when 5-HTTLPR was combined with the rs25531 SNP, and dis-
played a modest gene dose-dependent trend (P = 0.036) (Fig. 2B) with the dominant ‘long’ allele driving this 
significance for the incidence of diarrhoea (P = 0.013) (Supplementary Table 3). When separated by gender, sig-
nificant trends were not favoured by any one gender for the 5-HTTLPR dominant genotype (male: P = 0.012; 
female: P = 0.045) (Supplementary Table 3). Significance was lost when considering the 5-HTTLPR with rs25531 
SNP combined, but a trend was observed favouring females with the dominant genotype (P = 0.066).
In patients with imatinib-induced diarrhoea, carriers of the 09 alleles for the STin2 VNTR were more likely to 
experience diarrhoea: model B (P = 0.032) (Fig. 2C) and recessive model A (P = 0.028) (Fig. 2D). When stratify-
ing by gender this trend appeared to be influenced by females, though not significantly (Supplementary Table 3). 
However, these data must be viewed with caution owing to the low patient numbers of 09 allele carriers available 
for analysis: 9/186 (4.8%) male and 3/133 female (2.3%).
SeRt genotype does not correlate with diarrhoea grade. Diarrhoea toxicity grade was not signif-
icantly different between drug arms (P = 0.120; 95% CI = −0.020, 0.173) (Table 1). Diarrhoea experienced by 
all TKI-treated patients were largely grade 1 and 2 (75% and 14% of patients for imatinib, and 71% and 19% for 
dasatinib, respectively) (Table 1). Only three patients had grade 3 diarrhoea and there were no reports of grade 
4 diarrhoea. Diarrhoea toxicity grade was not significantly different between drug arms or gender (Table 1). 
Chi-square analysis with genotype did not show any significant correlations with diarrhoea toxicity grade for 
either the imatinib or dasatinib arms (Supplementary Table 3).
Discussion
Our analysis shows that in the SPIRIT2 trial, the incidence of diarrhoea was greater in imatinib- than in 
dasatinib-treated chronic myeloid leukaemia (CML) patients. Imatinib-induced diarrhoea was influenced by 
gender and SERT genotype. Carriers of the 5-HTTLPR ‘long’ allele or the STin2 VNTR 9-repeat allele were more 
likely to experience diarrhoea. Logistic regression identified that the dominant ‘long’ allele of the 5-HTTLPR 
explained ~6% of diarrhoea incidence in men, while age and the dominant ‘long’ allele of the 5-HTTLPR plus 
rs25531 SNP explained 10% of cases of diarrhoea in females. Furthermore, females younger than 65 were less 
likely to experience diarrhoea than those over the age of 65 (Supplementary Fig. 2). Although this trend was not 
Characteristics
imatinib dasatinib Comparison between TKI
No. (%) of patients No. (%) of patients P value (95% CI)
total male female total male female total male female
Gender 319 186 (58.3) 133 (41.7) 297 188 (63.3) 109 (36.7)
0.206 
(−0.127, 
0.027)
Age at diagnosis (years)
mean 54 54 53 53 52 54 0.404 
(−1.353, 
3.356)
0.097 
(−0.463, 
5.603)
0.429 
(−5.270, 
2.248)range 20–87 22–87 20–83 18–89 18–89 20–88
<65 243 (76.2) 139 (74.7) 104 (78.2) 227 (76.4) 151 (80.3) 76 (69.7) 0.941 
(−0.065, 
0.070)
0.193 
(−0.029, 
0.141)
0.134 
(−1.958, 
0.026)≥ 65 76 (23.8) 47 (25.3) 29 (21.8) 70 (23.6) 37 (19.7) 33 (30.3)
BMI
mean 27.9 26.8 27.8 27.0 27.2 26.8 0.056 
(−0.021, 
1.750)
0.142 
(−0.266, 
1.852)
0.202 
(−0.554, 
2.609)
range 19.0–59.8 19.0–59.8 19.8–46.6 18.5–44.2 18.5–43.9 19.3–44.2
Missing data 20 (6.3) 12 (6.5) 8 (6.0) 20 (6.7) 8 (4.3) 12 (11.0)
Platelet count (x109/L)
mean 513 463 582 501 444 598 0.688 
(−46.875, 
71.010)
0.585 
(−49.086, 
86.829)
0.762 
(−120.722, 
88.492)
range 16–2714 57–2212 16–2714 77–3140 77–2433 107–3140
Missing data 3 (0.9) 3 (1.6) 0 (0) 2 (0.7) 2 (1.1) 0 (0.0)
Diarrhoea incidence
Yes 144 (35.7) 55 (29.6) 59 (44.4) 79 (26.6) 45 (23.9) 34 (31.2) 0.015 
(0.018, 
0.165)
0.219 
(−0.034, 
0.146)
0.036 
(0.009, 
0.255)No 205 (64.3) 131 (70.4) 74 (55.6) 218 (73.4) 143 (76.1) 75 (68.8)
Toxicity grade
1 86 (75.4) 42 (76.3) 44 (74.5) 56 (70.9) 35 (77.8) 21 (61.8)
0.120 
(−0.020, 
0.173)
0.231 
(−0.044, 
0.182)
0.408 
(−0.100, 
0.246)
2 16 (14.0) 9 (16.4) 7 (11.9) 15 (19.0) 5 (11.1) 10 (29.4)
3 1 (0.9) 0 (0.0) 1 (1.7) 2 (2.5) 1 (2.2) 1 (2.9)
4 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Missing data 11 (9.7) 4 (7.3) 7 (11.9) 6 (7.6) 4 (8.9) 2 (5.9)
Table 1. Patient clinical information stratified by drug and gender. A T-test of independent samples was 
performed to compare differences between drug groups. Text in bold indicates statistical significance (P < 0.05). 
BMI = body mass index. Prevalence of diarrhoea is classified as incidence (yes or no) and toxicity grade (1 to 4).
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significant, it is consistent with the findings with bosutinib where 92% over the age of 65 years experienced diar-
rhoea6. By contrast, dasatinib-induced diarrhoea was not correlated with any covariate tested.
To our knowledge this is the first study to investigate the role of SERT genotype in drug-induced diarrhoea. 
Our patients largely had grade 1 or 2 diarrhoea and we had no patients with grade 4 diarrhoea. However, grade 
1 or 2 diarrhoeas (up to 1500 ml stool per day) can significantly impact a patient’s quality of life. The SERT gen-
otype has been investigated in the diarrhoea predominant irritable bowel syndrome (IBS-D), but studies have 
been contradictory in their assessment of which 5HTTLPR allele, ‘long’ or ‘short’, is responsible for enhanc-
ing diarrhoea symptoms29. It is important to note that not all studies considered age or gender, or the rs25531 
SNP that lies within the 5-HTTLPR region. Thus, many patients may have been incorrectly genotyped as ‘long’ 
when a G variant (LG) would in fact have converted this to a ‘short’ allele phenotype. Our analyses demonstrated 
some loss of significance with the incorporation of the rs25531 SNP within the 5-HTTLPR genotype highlight-
ing the subtle difference this may cause in changing phenotype and reported outcomes. Furthermore, a modest 
allele-dose-dependent pattern, with diarrhoea incidence, was observed with the incorporation of the rs25531 
SNP, compared with the 5-HTTLPR indel alone, suggesting that combining the 5-HTTLPR indel and rs25531 
SNP displays a more accurate dose dependent phenotype.
Less emphasis has been placed on the STin2 VNTR polymorphism with fewer published studies investigating 
this polymorphism compared with 5-HTTLPR. The shorter 10-repeat was shown to reduce SERT expression 
compared to the full length 12-repeat allele14. The shorter 9-repeat was not investigated, but it may be inferred by 
analogy that this allele would cause further reduced expression of SERT30. Owing to the low frequency of the 09 
allele, previous studies may have been under-powered (~100 patients) to determine any association19. Our cohort, 
however, comprised ~300 patients per drug treatment which allowed us to show a correlation between carriers of 
the 09 allele and imatinib-induced diarrhoea. With reduced expression of SERT being associated with a shorter 
Genotype
all patients (n = 616) imatinib patients (n = 319) dasatinib patients (n = 297)
obs 
(n)
exp 
(n) allele freq. χ2 P value
obs 
(n)
exp 
(n) allele freq. χ2 P value obs (n) exp (n) allele freq. χ2 P value
5-HTTLPR 
(rs4795541)
L 194 198 99 103 95 95
LS 311 302 L = 0.5674 164 156 L = 0.5674 147 146 L = 0.5673
S 111 115 S = 0.4326 0.4972 0.780 56 60 S = 0.4326 0.7119 0.701 55 56 S = 0.4327 0.0199 0.990
rs25531
A 535 535 277 278 258 259
AG 78 78 A = 0.9318 41 40 A = 0.9326 37 37 A = 0.9341
G 3 3 G = 0.0682 0.0075 0.996 1 1 G = 0.0674 0.1600 0.923 2 1 G = 0.0659 0.0723 0.964
STin2 VNTR 
(rs57098334)
12/12 242 236 121 122 121 113
12/10 262 272 145 142 117 130
12/09 16 19 8 9 8 10
10/10 86 79 12 = 0.6185 41 41 12 = 0.6191 45 38 12 = 0.6178
10/09 6 11 10 = 0.3571 2 5 10 = 0.3589 4 6 10 = 0.3552
09/09 4 <1 09 = 0.0244 39.8473 0.00001 2 <1 09 = 0.0219 24.1537 0.0002 2 <1 09 = 0.0269 19.0302 0.0019
Table 2. Hardy-Weinberg Equilibrium (HWE) calculations of patient SERT genotypes. P value is a measure of 
the deviation from HWE. Text in bold indicates significant P values. Serotonin-transporter-linked polymorphic 
region (5-HTTLPR). Intron 2, 17 bp variable number of tandem repeats (STin2 VNTR); 12, 10 and 9 tandem 
repeat alleles (12, 10 and 09 respectively). Allele frequency (allele freq.). Observed genotype (obs); expected 
genotype (exp); “long” allele (L); “short” allele (S). Text in bold indicates statistical significance (P < 0.05).
Figure 1. Diarrhoea incidence (yes or no) experienced by TKI treated CML patients. Patients stratified by 
imatinib (IM) and dasatinib (DAS) treatment and gender. Histogram represent data from Table 1. Actual patient 
numbers are incorporated within the histogram bars.
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STin2 VNTR sequence, our data support the hypothesis that a reduction in SERT activity would result in elevated 
circulating 5-HT concentrations leading to diarrhoea.
The 5-HTTLPR and rs25531 polymorphisms within our CML patients conformed to HWE. The deviation of 
the STin2 VNTR polymorphism from HWE may be related to its complex nature; we identified patients with 12, 
10 and 9 alleles in our cohort of 616 patients but did not identify an individual with the 7-repeat allele, and hence 
our sample size may not have been sufficient to determine the true population allele frequency of a polymorphism 
which consists of four, or possibly more, yet to be identified, alleles. Furthermore, we did not identify any signif-
icant differences in patient demographics, such as age, gender, BMI and platelet count, between the imatinib and 
dasatinib arms, and therefore any differences seen in diarrhoea AEs between the TKI arms may be attributed to 
the effect of the drug.
IBS-D is more prevalent in women than in men31, and the 5-HT3 receptor antagonist alosetron is more effec-
tive against IBS-D in women than men32. It is therefore of interest that we found trends suggesting that the effect 
of the SERT genotype may be more important in females with imatinib-induced diarrhoea. Our study however 
would have benefited from the inclusion of more females to support, or refute, these trends into statistically sig-
nificant findings.
We and other groups have only tested the three most commonly reported polymorphisms despite there being 
over 9700 documented SNPs within the SLC6A4/SERT gene33. Our a priori decision in not including further 
SNPs was due to the vast number and lack of functional information regarding all of these SNPs. Of course, the 
serotonin transporter is just one component in the serotonin pathway, which includes multiple 5-HT receptors 
(5-HTRs), the enzyme tryptophan hydroxylase 1 (TPH1) that is required to synthesise the supply of serotonin, as 
well as genes involved in post-receptor signalling cascades. Investigation of these SNPs may be worthwhile in the 
future, but will require a much larger sample size, and should probably proceed via a genome-wide association 
approach.
Our investigation was predicated on the hypothesis that TKI-induced diarrhoea was mediated through 
increased circulating 5-HT levels caused by SERT genotypes responsible for reducing SERT expression or activ-
ity. However, the associations we observed: (a) the ‘long’ allele 5-HTTLPR genotype, with or without rs25531, 
would reduce circulating 5-HT level, which is counterintuitive to our hypothesis; (b) carriers of the STin2 VNTR 
09 allele, which reduces SERT expression, were more likely to experience diarrhoea, which does fit our hypothe-
sis. It is clear that SERT functional activity is dependent on a number of factors, genetic and non-genetic, and is 
therefore highly complex. It is also possible that circulating 5HT levels may not necessarily correlate with 5HT 
concentrations in tissues, making the relationship with genotype even more complex. Nevertheless, the reason 
Covariate
all patients imatinib patients dasatinib patients
r2 P value OR (95% CI) r2 P value OR (95% CI) r2 P value OR (95% CI)
Drug 0.014 0.015 0.652 (0.462, 0.920) — — — — — —
Gender 0.021 0.002 0.585 (0.414, 0.826) 0.031 0.007 0.527 (0.331, 0.838) 0.009 0.174 0.694 (0.410, 1.174)
Age 0.009 0.049 1.012 (1.000, 1.024) 0.004 0.344 1.008 (0.992, 1.024) 0.016 0.077 1.016 (0.998, 1.033)
Age (≥ 65) 0.004 0.202 1.291 (0.872, 1.910) 0.003 0.436 1.234 (0.726, 2.098) 0.005 0.297 1.367 (0.760, 2.459)
BMI 0.011 0.034 1.035 (1.003, 1.069) 0.009 0.158 1.031 (0.988, 1.075) 0.009 0.176 1.035 (0.985, 1.088)
Platelets 0.000 0.997 1.000 (1.000, 1.000) 0.000 0.997 1.000 (0.999, 1.001) 0.000 0.955 1.000 (0.999, 1.001)
5-HTTLPR
biallelic 0.003 0.258 0.867 (0.676, 1.111) 0.023 0.021 0.666 (0.472, 0.940) 0.004 0.383 1.178 (0.815, 1.702)
rec 0.000 0.782 0.940 (0.605, 1.459) 0.000 0.997 1.001 (0.548, 1.828) 0.001 0.643 0.858 (0.448, 1.641)
dom 0.009 0.049 0.696 (0.486, 0.999) 0.052 0.0004 0.417 (0.255, 0.680) 0.004 0.358 1.304 (0.740, 2.299)
rs25531 biallelic 0.002 0.371 1.235 (0.777, 1.963) 0.001 0.587 1.195 (0.629, 2.270) 0.003 0.451 1.296 (0.660, 2.545)
5-HTTLPR + rs25531
biallelic 0.002 0.400 0.900 (0.704, 1.150) 0.024 0.020 0.663 (0.469, 0.937) 0.008 0.200 1.267 (0.882, 1.821)
rec 0.002 0.409 1.187 (0.790, 1.783) 0.007 0.221 1.429 (0.807, 2.528) 0.000 0.813 0.932 (0.519, 1.673)
dom 0.001 0.587 0.897 (0.606, 1.328) 0.027 0.012 0.509 (0.301, 0.862) 0.018 0.064 1.845 (0.965, 3.528)
STin2 VNTR
triallelic 0.002 0.366 1.074 (0.920, 1.255) 0.017 0.043 1.252 (1.007, 1.557) 0.003 0.470 0.917 (0.725, 1.160)
model B 0.002 0.364 1.100 (0.896, 1.351) 0.016 0.057 1.323 (0.992, 1.764) 0.002 0.513 0.902 (0.663, 1.228)
model A 0.001 0.477 1.092 (0.857, 1.390) 0.008 0.162 1.271 (0.908, 1.778) 0.001 0.666 0.924 (0.646, 1.322)
model A rec 0.002 0.348 0.803 (0.508, 1.270) 0.022 0.022 0.476 (0.252, 0.899) 0.004 0.373 1.389 (0.674, 2.864)
model A dom 0.000 0.746 1.059 (0.747, 1.503) 0.000 0.765 1.075 (0.670, 1.725) 0.000 0.961 1.013 (0.600, 1.712)
Covariate retained in model r2 r2
Gender 0.023 —
Gender with BMI 0.034 —
5-HTTLPR dom — 0.052
5-HTTLPR dom with gender — 0.078
Table 3. Logistic regression analysis of incidence of diarrhoea, by drug treatment, in CML patients. Body 
mass index (BMI). Age, in years, as a continuous variable (Age). Age, in years, defined as under 65, or 65 and 
over, as a binary variable (Age ≥ 65). Serotonin-transporter-linked polymorphic region alone (5-HTTLPR); or 
combined with rs25531 SNP (5-HTTLPR + rs25531). Intron 2, 17 bp variable number of tandem repeats (STin2 
VNTR); allelic model definitions described in Supplementary Table 2. Recessive allele (rec); dominant allele 
(dom). Text in bold indicates covariates included in the forward conditional regression model.
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for undertaking this study does have a strong biological plausibility, and the findings of the study suggest that 
further investigations of the role of 5HT in the pathogenesis of diarrhoea caused by TKIs, which is particularly 
troublesome for patients, is worthwhile. It may also allow the use of 5HT modulating drugs in the treatment of 
patients so that they can continue their therapy for CML.
An interesting finding from our study is that the association was seen with diarrhoea induced by imatinib but 
not by dasatinib. Although dasatinib and imatinib are both classed as Bcr-abl inhibitors to treat CML, they vary 
with respect to the off-target tyrosine kinases that they inhibit34, and it is therefore possible that kinases within the 
bowel may be differentially affected by these drugs as off-target effects. An interaction between the 5HT system 
and the kinase may therefore be required to elicit diarrhoea. Since the mechanisms of TKI-induced diarrhoea 
have not been fully elucidated, this is an area which merits further investigation.
In conclusion, our study has identified an association between diarrhoea induced by imatinib, but not by 
dasatinib, and SERT polymorphisms. The strength of our study is that the patients were recruited from a ran-
domised controlled trial (SPIRIT2) where patients will have had standardised assessment of efficacious and 
adverse events, as well as being randomised into different arms. However, despite the relatively large sample size, 
further studies will be needed to replicate this finding. It will also be important to understand the mechanistic 
basis of the role of 5HT in causing diarrhoea induced by TKIs, which should also include assessment of the 
off-target effects of the TKIs on the bowel kinome and the interaction with the 5HT pathway.
Methods
patient recruitment. The SPIRIT2 trial is a phase 3 prospective randomised comparison of imatinib 
(400 mg) versus dasatinib (100 mg) each daily in newly-diagnosed chronic phase chronic myeloid leukaemia 
(CML) patients (www.ClinicalTrials.gov; study identifier: NCT01460693). Ethical permission for the trial was 
granted by the London Research Ethics Committee, UK (REC ref# 07/H0718/90). Written informed consent was 
obtained from patients prior to their inclusion and the study conducted according to the declaration of Helsinki. 
The principal results from the study have been presented previously35. The patients’ ethnicity was not catalogued, 
but they were assumed largely to be Caucasians as they were recruited within the UK. Each arm of the study 
recruited 407 patients with the primary outcome measure described as 5-year event free survival. GI adverse 
events (AEs) were logged as occurrence of diarrhoea (i.e. yes or no) and grade was classified according to the 
Common Terminology Criteria for Adverse Events (CTCAE) system36.
DnA extraction. Genomic DNA was extracted from diagnostic patient bio-banked mononuclear cells using 
the AllPrep DNA/RNA Mini Kit (Qiagen®, Manchester, UK). Quantification, and quality assessment, of the DNA, 
Covariate
male imatinib patients female imatinib patients
r2 P value OR (95% CI) r2 P value OR (95% CI)
Age 0.002 0.589 0.994 (0.973, 1.016) 0.055 0.022 1.032 (1.005, 1.060)
Age (≥ 65) 0.001 0.740 0.883 (0.424, 1.841) 0.030 0.084 2.091 (0.906, 4.827)
BMI 0.024 0.080 1.055 (0.994, 1.120) 0.000 0.926 1.003 (0.945, 1.064)
Platelets 0.007 0.355 0.999 (0.998, 1.001) 0.000 0.832 1.000 (0.999, 1.001)
5-HTTLPR
biallelic 0.029 0.053 0.610 (0.370, 1.007) 0.018 0.183 0.723 (0.448, 1.166)
rec 0.001 0.799 0.892 (0.369, 2.156) 0.000 0.992 0.996 (0.425, 2.331)
dom 0.049 0.010 2.420 (1.234, 4.744) 0.042 0.042 0.470 (0.227, 0.972)
rs25531 biallelic 0.010 0.245 1.638 (0.713, 3.766) 0.003 0.616 0.771 (0.279, 2.130)
5-HTTLPR + rs25531
biallelic 0.022 0.089 0.407 (0.407, 1.066) 0.028 0.099 0.652 (0.392, 1.084)
rec 0.010 0.271 0.631 (0.278, 1.433) 0.005 0.470 1.353 (0.595, 3.075)
dom 0.020 0.105 1.807 (0.884, 3.694) 0.038 0.053 0.449 (0.200, 1.009)
STin2 VNTR
triallelic 0.028 0.054 1.323 (0.996, 1.758) 0.009 0.338 1.185 (0.837, 1.678)
model B 0.034 0.035 1.510 (1.030, 2.212) 0.003 0.561 1.143 (0.729, 1.792)
model A 0.021 0.099 1.479 (0.929, 2.354) 0.001 0.761 1.081 (0.656, 1.781)
model A rec 0.017 0.129 1.933 (0.825, 4.532) 0.031 0.081 2.444 (0.895, 6.669)
model A dom 0.012 0.221 0.658 (0.337, 1.287) 0.007 0.394 1.357 (0.672, 2.742)
Covariate retained in model r2 r2
5-HTTLPR dom 0.059 —
Age — 0.055
Age with 5-HTTLPR + rs25531 dom — 0.097
Table 4. Logistic regression analysis of incidence of diarrhoea, stratified by gender, in imatinib treated CML 
patients. Body mass index (BMI). Age, in years, as a continuous variable (Age). Age, in years, defined as under 
65, or 65 and over, as a binary variable (Age ≥ 65). Serotonin-transporter-linked polymorphic region alone 
(5-HTTLPR); or combined with rs25531 SNP (5-HTTLPR + rs25531). Intron 2, 17 bp variable number of 
tandem repeats (STin2 VNTR); allelic model definitions described in Supplementary Table 2. Recessive allele 
(rec); dominant allele (dom). Text in bold indicates covariates included in the forward conditional regression 
model.
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was performed on the Nanodrop 2000 UV-VIS Spectrophotometer (ThermoFisher Scientific, Loughborough, 
Leicestershire, UK). Samples were stored at −20 °C until required.
SERT/SLC6A4 Genotyping. The SERT/SLC6A4 polymorphisms multiplex PCR assay was adapted from 
Wendland et al.37 Primers were synthesised by MWG Eurofins, Germany (Supplementary Table 1). Patient 
genomic DNA (80 ng) was amplified using OneTaq enzyme (Promega, Southampton, UK) with GC Buffer (New 
England Biolabs, Herts, UK), dNTPs (10 mM final conc.), and equimolar concentrations (50pmol final concen-
tration) of forward and reverse primers for both 5-HTTLPR and VNTR. PCR cycling conditions were: 94 °C for 
30 secs; 35 cycles of 94 °C for 30 secs; 64 °C for 30 secs; 68 °C for 30 secs; and 68 °C for 5 mins. To determine pres-
ence of the rs25531 SNP within the 5-HTTLPR region, a restriction enzyme digest was performed on the PCR 
product. Seven microliters of product was digested with MspI in CutSmart buffer (New England Biolabs, Herts, 
UK) at 37 °C for 90 mins. PCR products were separated by 2.5% 0.5x TBE-buffered agarose gel and visualised with 
ethidium bromide using a UV trans-illuminator.
Interpretation of the PCR products expected is described in Supplementary Table 1. Ten percent of the sam-
ples were duplicated, for assay reliability, and genotypes were reproducible and in complete concordance. SERT 
genotypes, dominant and recessive models, were classified as shown in Supplementary Table 2.
Statistical analyses. Differences between treatment arms for age, gender, body mass index (BMI), plate-
let count and diarrhoea incidence were performed using a comparison of means test for independent samples. 
Correlations between genotype and categorical and ordinal outcomes were performed by Chi-square (χ2) anal-
yses, generating Pearson and Fisher’s Exact tests. One-way ANOVA tests were performed with linear covariates. 
Logistic regression analyses were performed to describe the influence of covariates on diarrhoea. These analyses 
were performed using the IBM SPSS statistics software v24 (IBM Corp., Armonk, NY, USA).
Data availability
All data generated or analysed during this study are included in this published article (and its Supplementary 
Information files).
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